TITLE:
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Topiramate for Lennox-Gastaut Syndrome

CONDITION:
Lennox-Gastaut Syndrome

INTERVENTION:
topiramate

SUMMARY:

      OBJECTIVES:

      I. Evaluate the safety and efficacy of oral topiramate in patients with Lennox-Gastaut
      syndrome.
    

DETAILED DESCRIPTION:

      PROTOCOL OUTLINE: This is a randomized, double-blind study. Following a 28-day baseline
      period, patients are randomly assigned to oral topiramate or placebo. The dose of study
      medication is titrated over the first 3 weeks; the maintenance dose is administered for the
      next 5 weeks.

      Extended topiramate treatment is available to all patients after randomized therapy.
    

ELIGIBILITY:
Gender: All
Age: 4 Years to 30 Years
Criteria:

        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics-- Lennox-Gastaut syndrome Slow spike and wave pattern on
        electroencephalogram At least 60 seizures with atypical absence and drop attacks within 1
        month Seizure types allowed in addition to those above: Tonic Tonic-clonic Myoclonic Minor
        motor Absence of progressive lesion confirmed by computerized tomography or magnetic
        resonance imaging No change documented by physical exam subsequent to imaging No
        generalized status epilepticus within 3 months while complying with drug therapy No
        seizures resulting from progressive disease, e.g.: Active infection Neoplasm Metabolic
        disorder No anoxic episode requiring resuscitation within 1 year --Prior/Concurrent
        Therapy--

        1 or 2 concurrent maintenance antiepileptics required At least 6 months since
        corticotropin At least 60 days since acetazolamide or zonisamide At least 60 days since
        investigational drug or device No ketogenic diet --Patient Characteristics--
        Hematopoietic: No hematological abnormality within 2 years Hepatic: No hepatic disease
        within 2 years Renal: No nephrolithiasis No other renal disease within 2 years
        Cardiovascular: No clinically significant electrocardiographic abnormality No
        cardiovascular disease within 2 years Pulmonary: No respiratory disease within 2 years
        Other: Weight at least 25 lb (11.5 kg) No medical disease within 2 years, e.g.: Rheumatic
        fever Gastrointestinal abnormality Malignancy No psychiatric or mood disorder inconsistent
        with Lennox-Gastaut within 6 months requiring any of the following: Electroconvulsive
        therapy Antidepressants Anxiolytics Antipsychotics Lithium carbonate No history of alcohol
        or drug abuse No history of poor compliance on past antiepileptic therapy Able to take
        medication and maintain seizure calendar (assistance allowed) Adequate parental
        supervision 1 parent/guardian with adequate English fluency if English not patient's
        primary language The following required of fertile women: Negative serum-beta pregnancy
        test immediately prior to entry Normal menstrual flow for 3 months prior to entry
        Medically acceptable form of contraception during study
      
